Weekly shot could free hypoparathyroidism patients from daily pills

NCT ID NCT07699471

Recruiting now Disease control Sponsor: MBX Biosciences Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether a once-weekly injection of canvuparatide (MBX 2109) can help adults with hypoparathyroidism reduce their daily calcium and vitamin D supplements while keeping blood calcium in a healthy range. The study includes 160 participants who will receive either the drug or a placebo for 26 weeks, followed by an open-label extension. The goal is to see if more people on the drug can become independent of active vitamin D and high-dose calcium supplements compared to those on placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: canvuparatide (MBX 2109)
What this could lead to: If successful, this once-weekly injection could allow many people with hypoparathyroidism to reduce or stop daily calcium and vitamin D supplements while keeping their blood calcium levels normal.
What could go wrong: This is a Phase 3 trial, so earlier results were promising but not definitive. The treatment may not work for everyone, and side effects or the need for dose adjustments are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypoparathyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOPARATHYROIDISM

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-••••

Locations

MBX Biosciences Investigational Site
RECRUITING

Homestead, Florida, 33030, United States
MBX Biosciences Investigational Site
RECRUITING

Shavano Park, Texas, 78231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.